BiogenBIIB
NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation
American biotech company focused on neurological diseases — including Alzheimer's (Leqembi, with Eisai) and MS.
Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.
Key metrics
Market cap
$29.4B
Price
$199.31
Today
+0.2%
Return YTD
+13.0%
Return 1Y
+49.5%
P/E
21.4
P/S
3.0
P/B
1.6
Data as of 2026-07-10 · updates daily after U.S. close
Theme exposure
In the value chain
Products & services
- Alzheimer's (Leqembi)
- Multiple sclerosis
- Rare diseases
Competitors
- Eli Lilly (Alzheimer's)
- Roche
- Novartis
Risks
- Leqembi uptake
- Declining MS revenue
Same segment: Biotech & innovation
See where Biogen sits in the full Medicine, pharma & life science map — every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →